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Oral Immunotherapy in IgE-Mediated Cow’s Milk Protein Allergy
Jody Bauer PA-S
Abstract
Cow’s milk allergy prevalence in children has been increasing significantly
over the last several decades. The diagnosis of a cow’s milk allergy (CMA)
can occur through several methods such as signs and symptoms, double blind
oral food challenge, skin prick testing, IgE and IgG4 serum levels. Currently,
there are no treatments beyond strict allergen avoidance. The patient’s quality
of life is impacted with the fear of inadvertent exposure resulting in allergic
reactions that may be life threatening. Recent studies have explored
desensitization to CM using oral immunotherapy (OIT), subcutaneous
immunotherapy, and sublingual immunotherapy (SLIT). Research has found
that desensitization will decrease the risk of allergic response to accidental
exposures with the hope of lifelong tolerance to CM. The findings indicate
means of successful desensitization, lifelong tolerance through maintenance
regimens, and methods of increasing safety during desensitization.

Cow’s Milk Allergy Facts
 2-7.5% of children <1 year of age have CMA (Ludman et al., 2013)
 2 % of adults in developed countries have CMA (Sackeyfio et al., 2011)
 39% of children with food allergies will have a severe reaction once every
four years (Umetsu, 2014)
 125,000 emergency room visits yearly (Levy et al., 2014)
 15,000 food induced anaphylaxis episodes yearly (Levy et al., 2014)
 Economic impact is estimated at 25 billion dollars per year in the United
States (Umetsu, 2014)
 Physical and Psychological burden
 53-57% of children outgrow CMA by 5 years of age
 CMA is more likely to persist in children with asthma or allergic rhinitis
(Ludman et al., 2013)
 No cure, current treatment is strict avoidance of cow’s milk

Statement of the Problem
 Accidental exposures resulting in life threatening reactions

Research Questions
 Does giving increasing doses of cow’s milk (OIT) improve tolerance to
exposure to cow’s milk protein? Yes. Oral immunotherapy and SLIT
improved CM tolerance in children with CMA determined by Skripak et al.
(2008), Keet et al. (2012), Kim et al. (2011), Nadeau et al. (2011), and
Levy et al. (2014). Researchers compared techniques of desensitization
(OIT, SLIT, heated CM) and methods of adverse reaction reduction
(heated CM, anti-IgE pharmaceuticals).
 Are there methods to maintain long-term tolerance to cow’s milk
allergy? Currently, no medications or therapy plans have produced lifelong
tolerance without maintenance therapy. Keet et al. (2012), Kim et al.
(2011), Salmivesi et al. (2013), and Pajno (2013) researched approaches to
maintain a high CM threshold and therefore long-term CM tolerance.
Approaches to sustain desensitization through maintenance therapy (daily
vs twice weekly) are required. A decline in CM threshold occurs in
participants previously desensitized without maintenance therapy Skripak
et al. (2008).
 Are there adjunctive therapies used with oral immunotherapy to
decrease the frequency and severity of adverse reactions due to
therapy? Five studies have reviewed the impact of adverse reactions in the
development of OIT for CMA: Skripak et al. (2008), Keet et al. (2012),
Kim et al. (2011), Nadeau et al. (2011) and Lucendo et al. (2014).
Researchers noticed an increase in adverse reactions with OIT. Skripak et
al. (2014) observed a statistically significant increase between OIT and
placebo (p = .02). Adverse multisystem reactions occurred more frequently
in those receiving OIT compared to placebo or SLIT (Keet et al., 2012).
Omalizumab allowed a safer, rapid desensitization and is continuing to be
researched.

Applicability to Clinical
Practice
 Lifestyle modifications, strict cow’s milk avoidance, continue to have
possibilities of unintentional exposures resulting in IgE-mediated reactions.
 Educate family on new research to improve patient’s quality of life both
physical and psychological.
 Raising the CM threshold in CMA patients has the potential to reduce
emergent medical expenses considerably.
 Involves long term maintenance therapy
 Safety from adverse reactions continues to preserve the absence of OIT in
the clinical setting.

 Double-blind, placebo-controlled food challenge
(DBPCFC)GOLD STANDARD
 Reoccurrence of symptoms after ingestion of the
suspected food and resolution of these symptoms
when strict avoidance is maintained
 Skin prick testing (SPT) with >3 mm wheal
(Sensitive: 95% NPV, 50% PPV)
 Serum food-specific IgE levels with Phadia
ImmunoCAP assay (95% clinical reactions)

Pathophysiology

 Increasing prevalence of cow’s milk allergy in children
 ONLY treatment option is strict avoidance

How is Cow’s Milk
Allergy Diagnosed?

Innate Immunity
Characteristics Barriers

Inflammatory Response

Adaptive (Acquired) Immunity

Level of
defense

First line of defense against infection
and tissue injury

Second line of defense; occurs as a
response to tissue injury or infection

Third line of defense; initiated when innate
immune system signals the cells of adaptive
immunity

Timing of
defense

Constant

Immediate response

Delay between primary exposure to antigen
and maximum response, immediate against
secondary exposure to antigen

Specificity

Broadly specific

Broadly specific

Response is very specific toward “antigen”

Cells

Epithelial cells

T lymphocytes, B lymphocytes,
macrophages, dendritic cells

Memory

No memory involved

Mast cells, granulocytes (neutrophils,
eosinophils, basophils), monocytes
(macrophages), natural killer (NK)
cells, platelets, endothelial cells
No memory involved

Peptides

Defensin, cathelicidins, collectins,
lactoferrin, bacterial toxins

Complement, clotting factors, kinins

Protection

Protection includes anatomic barriers
(i.e., skin and mucous membranes),
cells and secretory molecules or
cytokines (e.g., lysozymes, low pH of
stomach and urine) and ciliary activity

Protection includes vascular response,
cellular components (e.g., mast cells,
neutrophils, macrophages, secretory
molecules or cytokines, and activation
of plasma protein systems

Specific immunologic memory by T and B
lymphocytes
Antibodies, complement
Protection includes activated T and B
lymphocytes, cytokines, and antibodies

Type IV cell-mediated hypersensitivity reactions are:
 Initiated by haptens that react with normal self-proteins in the skin and
remain contained to the point of contact at which a cell-mediated immune
response occurs.
 Cytotoxic T lymphocytes (Tc cells) or lymphokine-producing Th1 cells
directly kill foreign or abnormal cells as well as activate other cells to assist.
 Cow’s milk protein, Type IV cell mediated reaction, results in tissue
destruction in the gastrointestinal tract and contact dermatitis.
Type Name of
Reaction

Rate of
Class of Antibody
Developement Involved

Principal Effector
Cells Involved

Complement
Participation

Examples of Disorders

I
II

Immediate
Immediate

IgE
IgG
IgM
IgG
IgM

Mast cells
Macrophages in
tissues
Neutrophils

No
Frequently

Seasonal allergic rhinitis
Autoimmune thrombocytopenic purpura, Graves
disease, autoimmune hemolytic anemia
Systemic lupus erythematosus

None

Lymphocytes
Macrophages

III

IV

IgE-mediated
Tissuespecific
Immune
complexmediated
Cell-mediated

Immediate

Delayed

Yes

No

The human body has 3 mechanisms of self defense:
1. Barriers
2. Inflammatory Response
3. Adaptive (Acquired) Immunity

Contact sensitivity to poison ivy and metals
(jewelry)
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Adaptive Immunity is critical to a Type I hypersensitivity
response to cow’s milk by utilizing antibodies as memory
cells which recognize the cow’s milk antigen as foreign,
prompting an IgE-mediated reaction involving both
antigens, antibodies, and ultimately mast cell degranulation.

Literature Review
 Oral Immunotherapy vs Placebo. Skripak et al. (2008) performed a 23
week RCT in 20 children ages 6-21 with IgE-mediated Cow’s Milk Allergy
(CMA) to desensitize children. Participants were escalated to a dose of 500
mg (15 mL of milk), the dose was maintained for 13 weeks followed by a
Double Blind Placebo Controlled Food Challenge (DBPCFC). The increase
CM threshold was statistically significant (p= .002) in the Oral
Immunotherapy (OIT) group in addition to a 76% increase in IgG4 (p =
.002). Adverse reactions were statistically significant (p=.02) with OIT
group having more reactions.
 Cow’s Milk Oral Immunotherapy vs. Sublingual Immunotherapy. Keet
et al. (2012) performed a 66 week study in 30 children ages 6-11 with
IgE-mediated CMA evaluating the safety and efficacy of sublingual
immunotherapy versus oral immunotherapy. OIT participants tolerated the
8g CM challenge at T5 (p = .002) compared to the SLIT group. Adverse
reactions were not statistically significant between the SLIT vs OIT groups
(p = .73), however multisystem reactions were (p = <.001) with increased
incidence in the OIT group. SLIT was limited by the route of
administration and a maximum dose of 7 mg compared to the OIT group 12 g.
 Heated Milk Used to Accelerate Tolerance. Kim et al. (2011) conducted a
37 month study of 88 children ranging in age from 8-75 months old (6 ¼
years) and demonstrated accelerated heated CM tolerance and increased
CM threshold in 74% of the study participants. Researchers observed a
significant difference (p= .04) between adverse reactions between baked
milk-tolerant and baked-milk reactive during DBPCFC in the follow up
period.
 Anti-IgE Therapy (omalizumab) Plus Oral Immunotherapy. Nadeau et
al. (2011) performed a phase I study in 11 children ages 7-17 with IgEmediated CMA to accelerate desensitization and decrease adverse reactions.
Omalizumab was administered every 2-4 weeks for 9 weeks at which time
cow’s milk was introduced with a desensitization goal of 1000 mg. The
dose of CM was escalated weekly over the next 7-11 weeks with a goal of
7250 mg (220 mL milk). Adverse reactions were 1.6% of dose
administrations. This study was limited by size, not having a placebo
group, phase I study, and length of study.
 Predictors of OIT Success. Levy et al. (2014) explored oral
immunotherapy to predict successful desensitization and increase the cow’s
milk protein threshold. Two hundred eighty participants with IgE-mediated
CMA, ages 4-27 years (mean 7.5) over 10 months enrolled. Levels of CM
specific IgE and IgG4 were followed. Researchers found participants that
successfully reached a desensitization goal of 7.2 g of CM were shown to
have higher levels of IgG4.
 What Is the Maintenance Therapy to Maintain Tolerance. Salmivesi et
al. (2013) explored further if successfully desensitized CMA participants
could maintain desensitization with daily maintenance therapy for 3 years.
Researchers found 79% of CMS participants maintained significant
desensitization. Pajno et al. (2013) studied daily vs twice weekly
maintenance therapy in a 12 month study with 38 children ages 4-13 years
with no statistical significance between dosing regimens (p= .08).
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